Acrivon Therapeutics, INC 8-K filings

Acrivon Therapeutics announced its second quarter 2026 financial results, highlighting progress in its ACR-368 and ACR-2316 clinical programs and providing an updated cash runway into late 2027.

Acrivon Therapeutics stockholders approved an amended equity incentive plan and elected two Class I directors at the 2026 annual meeting.

Acrivon Therapeutics reported Q1 2026 financial results, highlighting progress in its oncology programs ACR-368 and ACR-2316, with cash runway extending into Q3 2027.

Acrivon Therapeutics announced positive clinical trial results for ACR-368 in endometrial cancer and ACR-2316 in lung cancer, alongside a cash runway into Q2 2027.

Acrivon Therapeutics presented positive interim Phase 2b data for ACR-368 in endometrial cancer, particularly in the serous subtype, highlighting significant objective response rates and a favorable safety profile.

Acrivon Therapeutics presented positive clinical data for its lead oncology candidates, ACR-368 and ACR-2316, alongside updates on its AP3 platform and a new development candidate, ACR-6840.

Acrivon Therapeutics announces positive Phase 2b clinical data for ACR-368 in endometrial cancer, initial Phase 1 data for ACR-2316, nominated a new development candidate ACR-6840, and reported preliminary cash of $119 million, extending its operational runway into Q2 2027.

Acrivon Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical-stage precision medicine pipeline, including advancements for ACR-368 and ACR-2316.

Acrivon Therapeutics provided a corporate presentation detailing strong preclinical synergy for its lead candidates with immune checkpoint inhibitors and positive clinical data for ACR-368 in endometrial cancer.

Acrivon Therapeutics reported a net loss of $21.0 million for Q2 2025, while advancing its clinical programs ACR-368 and ACR-2316, and extending its cash runway into Q2 2027.

Acrivon Therapeutics, Inc. announced the successful election of three Class III directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm at its 2025 annual meeting of stockholders.

Acrivon Therapeutics announces positive clinical data for ACR-368 in endometrial cancer and reports its first quarter 2025 financial results, highlighting a net loss of $19.7 million and a cash balance of $164.8 million.

Acrivon Therapeutics appoints Mansoor Raza Mirza, M.D., a distinguished oncologist, as its new Chief Medical Officer, effective April 9, 2025.

Acrivon Therapeutics reports promising clinical data for ACR-368 in endometrial cancer patients and extends its cash runway into 2027.

Acrivon Therapeutics focuses on endometrial cancer and ACR-2316, citing encouraging ACR-368 data and deprioritizes ovarian and bladder cancer programs.

Acrivon Therapeutics announces the appointment of Adam Levy as Chief Financial Officer, effective April 1, 2025, following the departure of Rasmus Holm-Jorgensen.

Acrivon Therapeutics reported positive clinical data for its ACR-368 drug in endometrial cancer, with a 62.5% overall response rate, and provided a business update for the third quarter of 2024.

Acrivon Therapeutics has dosed the first patient in a Phase 1 clinical trial for ACR-2316, a novel WEE1/PKMYT1 inhibitor designed using their AP3 platform.

Acrivon Therapeutics reported a 62.5% objective response rate in OncoSignature-positive endometrial cancer patients treated with ACR-368 and announced the advancement of ACR-2316 into Phase 1 trials.

Acrivon Therapeutics announced positive results from its Phase 2 trial of ACR-368, progress with ACR-2316, and a successful $130 million private placement.

Acrivon Therapeutics held its 2024 annual meeting, electing three Class II directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.

Acrivon Therapeutics announced positive initial clinical data for ACR-368, accelerated development of ACR-2316, and secured $130 million in private financing.

Acrivon Therapeutics reports a 50% confirmed objective response rate in OncoSignature-positive patients in a Phase 2 trial of ACR-368 and accelerates the IND filing for ACR-2316.

Acrivon Therapeutics has successfully raised $130 million through a private placement to fund the development of its precision oncology pipeline.

Acrivon Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in clinical trials and the development of its precision oncology platform.

Acrivon Therapeutics has appointed Santhosh Palani, Ph.D., CFA, a seasoned healthcare investor and former drug developer, to its Board of Directors, effective March 4, 2024.

Acrivon Therapeutics has appointed Ivana Magovcevic-Liebisch, a seasoned industry executive, to its board of directors, effective February 8, 2024.